New Episode of Hump Day Hormones is LIVE!

“If testosterone works so well, why isn’t it approved?”

“Is it not safe, or is there something else going on?”

If you’ve ever questioned why testosterone for women is still considered “off-label,” this episode is for you. This is not a simple answer, and it has a lot less to do with effectiveness than most people think.

In this episode, we break down:

• The difference between clinical guidelines and FDA approval

• Why lack of pharmaceutical incentive stalled large-scale trials

• The real safety concerns regulators wanted answered

• Why long-term data is still limited

• Why measuring sexual desire makes trials more complex

• How dosing and product design complicate standardization

We also walk through what actually happened historically. Testosterone has been approved for men for decades and is even used in other countries for women, but in the U.S., timing, funding, and regulation all collided, especially after the Women’s Health Initiative, slowing research and halting momentum.

When companies tried to bring female-specific products to market, they did not fail because they didn’t work. They ran out of time, funding, or both.

Here’s the reality:

The FDA approves products, not hormones, and without the right funding, formulation, and long-term data, approval never happened.

So instead, we are left with off-label prescribing, compounded options, and inconsistent dosing, not because testosterone doesn’t work, but because the system never fully supported bringing it to market for women.

This episode also breaks down what testosterone is actually proven to help with, what is still emerging, and what it is not meant to be used for, so you can understand where it fits and where it doesn’t.

Share this with the woman who’s been told, “If it worked, it would already be approved.”